ClinicalTrials.gg
CompletedNCT05754411Updated Dec 7, 2023

[14C] Study on Mass Balance and Biotransformation of STI-1558 in Healthy Chinese Adult Male Subjects

A Phase 1 interventional study of [14C]STI-1558 in COVID-19, sponsored by Zhejiang ACEA Pharmaceutical Co. Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-07.

Sponsored by Zhejiang ACEA Pharmaceutical Co. Ltd. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 472 studies in COVID-19 with a site in China — 53 open to participants now, 75 under way, 8 of them phase 3. COVID-19 · China.

Enrollment
316th of 330
6 · median 200
Started
2023
with 103 others
Phase 1
67 of 472
7 open now
Registered
364th of 472
by date

Among the 472 studies in COVID-19 with a site in China, this one is the 316th largest by enrollment of the 330 interventional ones that give a count, is one of 104 that started in 2023, is one of 67 in phase 1, and was the 364th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

53 of the 472 studies in COVID-19 with a site in China are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 472 studies in COVID-19 with a site in China, or all of them as a file.
02

Study summary

This trial adopts a single-center, single-dose, single-period, non-randomized, open-label study design. It is planned to enroll 6\~8 healthy male subjects, and each subject receives single oral administration of drug solution containing 600mg/approximately 100µCi [14C]STI-1558 under fasting conditions on trial D1. The whole blood, plasma, urine and stool samples are collected at specified time points/intervals during the trial. The pharmacokinetic parameters of the total radioactivity in plasma and whole blood, the material concentration ratios of the total radioactivity in plasma and whole blood, and the material balances are obtained by testing the total radioactivity of [14C]STI-1558 in plasma, whole blood, urine and feces. Meanwhile, using isotope tracer and mass spectrometry techniques, the main pathways and characteristics of metabolism and elimination of STI-1558 in humans are obtained through the quantification of radioactive metabolite profiles and the structure identification of the main metabolites in plasma, urine and feces of the subjects. The entire duration of trial is expected to be 5 months.

Read the detailed description

The experiment was carried out in two steps :

Step 1 : Two qualified male subjects were enrolled in the study. After screening, the qualified subjects were admitted to the clinical research center after the D-2 was again verified by the inclusion and exclusion criteria. After admission, they were trained in medication, urine and feces collection procedures to ensure that they could perform relevant operations according to the program and SOP requirements. D-1 began to collect random urine samples ( -24 h\~0 h ) and D-2 began to collect random fecal samples ( -48 h\~0 h ). Subjects tested D1 morning fasting oral test drugs. All urine and feces samples excreted within the specified time interval of 0\~336 h and blood samples at the specified time point of 0\~168 h were collected. The test adopts the method of phased detection. According to the test results, it is judged whether the collection of blood, urine and feces samples can be terminated in advance or the collection needs to be continued. If the study finds that the collection time of biological samples exceeds the planned time ( i.e., blood 168 h, urine and feces 336 h ), the collection will be continued at an interval of 24 h ( or according to the researcher 's judgment, the integer multiple of 24 h ) until the judgment criteria for the termination of sample collection specified in the scheme are met. Safety monitoring continued until sample collection was completed.

Step 2 : 4-6 qualified male subjects were selected and blood, urine and feces samples were collected at the specified time points / intervals. The operation is the same as the first step. According to the test results of the first step test, determine whether the test process needs to be adjusted.

Criteria for terminating collection:

Excreta : The total radioactivity of biological samples ( urine + feces ) collected from each subject exceeded 90 % of the dose, and the total radioactivity of biological samples ( urine + feces ) collected for two consecutive days was less than 1 % of the dose ; radioactive blood samples : plasma radioactive concentration \< 3 times plasma background value.

Finally, whether the subjects should terminate the collection of the corresponding samples was determined by the researchers based on the results of the radioactive test, the safety results and the actual situation, and the opinions of the sponsors.

All subjects were required to complete the test procedure according to the program requirements during their stay in the clinical research center. The subjects who met the radioactive recovery conditions were collected in the laboratory examination samples, and no clinically significant abnormalities were found in the clinical observation, and the group could be confirmed by the researchers. If the abnormality is found to have clinical significance, the subjects will need to remain in the research center for observation or after the comprehensive evaluation of the researchers, agree to leave the research center and return to the hospital for regular review ( according to the requirements of the researchers ), follow-up until the normal or abnormal level is returned to normal or not clinically significant or acceptable to the researchers.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing to sign form;
  • Chinese healthy male subjects between 18-45 years of age (inclusive);
  • Weight: weight ≥ 50.0kg and (BMI) between 19.0\~26.0kg/m2 (inclusive);
  • Male subjects of who have no birth plans throughout the study period and for 12 months after the end of study, and agree to take measures with their sexual partners during this period, such as condoms, contraceptive sponges, contraceptive gels, contraceptive films, intrauterine devices, oral or injected contraceptives (only suitable for the period after end of trial), subcutaneous implants (only suitable for the period after end of trial) or other contraceptive measures;
  • Able to communicate well with the investigator and able to complete the trial in accordance with the protocol.

Exclusion criteria

Exclusion Criteria:

Laboratory tests:

  • Subjects who have abnormalities through comprehensive physical examinations, vital signs, routine laboratory tests (blood routine, blood biochemistry, 4-item coagulation function, urine routine, stool routine + occult blood, etc.) and 12-lead ;
  • Thyroid-stimulating hormone (TSH) > (upper limit of normal); or free triiodothyronine (FT3) > ULN; or free thyroxine (FT4) > ULN;
  • Blood amylase or lipase > ULN;
  • Subjects who have any positive tests for surface antigen, antibody, treponema pallidum antibody, or combined antigen/antibody test (primary screening);

Medication history:

  • Subjects who have received any products (including marketed products) or participated in any clinical trials with drugs/devices within 3 months prior to screening;
  • Subjects who have used any drugs that inhibit or induce liver drug metabolizing enzymes within 30 days prior to screening (such as: inducers - barbiturates, carbamazepine, phenytoin, rifampicin, dexamethasone, rifabutin, rifapentine, etc.; inhibitors - SSRI antidepressants, cimetidine, diltiazem, macrolides, verapamil, imidazole antifungals, sedative-hypnotics, verapamil, fluoroquinolones, antihistamines, etc.);
  • Subjects who have taken any drugs that inhibit gastric acid secretion and gastric antiacids within 14 days prior to screening, such as H2 receptor antagonists (cimetidine, ranitidine, famotidine, nizatidine, roxatidine, etc.); proton pump inhibitors (omeprazole, lansoprazole, rabeprazole, pantoprazole, esomeprazole, etc.); and cholinergic receptor blockers (atropine, pirenzepine, etc.);
  • Subjects who have used prescribed drugs, non-prescribed drugs, or health care medicines including western medicines or Chinese patent medicines within 30 days prior to administration (see exclusion criteria 6 and 7 for restrictions on liver drug metabolizing enzyme drugs, drugs that inhibit gastric acid secretion, and gastric antiacids); or have been vaccinated within 30 days prior to administration or plan to be vaccinated during the trial and within 30 days after end of trial;

Medical history and surgery history:

  • Subjects with any history of clinically significant diseases or diseases or conditions that may affect the trial results in opinion of the investigator, including but not limited to history of motor system, nervous system, endocrine system, circulatory system, respiratory system, digestive system, urinary system and reproductive system diseases;
  • Subjects with previous history of organic heart diseases (such as history of heart failure, history of myocardial infarction, history of angina pectoris), history of unexplained arrhythmia (such as history of ventricular tachycardia, history of syndrome) or symptoms or family history (with genetic evidences or close relatives who died suddenly from cardiac causes at a young age) of QT prolongation syndrome;
  • Subjects with coagulation disorders, hemorrhagic diseases (such as hemophilia, purpura) or hemorrhagic symptoms (such as hematemesis, melena, hemorrhage of gastrointestinal tract, serious or recurrent epistaxis, hemoptysis, obvious hematuria or intracranial hemorrhage);
  • Subjects who have suffered esophageal reflux or peptic ulcer diseases, or have received any previous surgical operations that may affect drug absorption (such as cholecystectomy) within 3 months prior to screening;
  • Subjects who have received major surgeries within 6 months prior to screening or have surgical incisions that have not fully healed (see exclusion criteria 12 for surgical operation restrictions that may affect drug absorption); major surgeries include, but are not limited to, any surgeries with significant hemorrhage risks, prolonged general anesthesia periods, incisional or obvious traumatic injuries (except for appendicitis surgery or anal prolapse surgery that has recovered);
  • Subjects with significant allergic conditions, including subjects who are clearly allergic to two or more other drugs or food ingredients; or subjects with previous history or family history of allergic skin diseases; or subjects who have special dietary requirements and cannot follow a unified diet;
  • Subjects with mental disorders or previous history of mental disorders;
  • Subjects with perianal diseases with concurrent hemorrhoids or regular/current hematochezia;
  • Subjects with habitual constipation or diarrhea, irritable bowel syndrome, or inflammatory bowel diseases;

Living habits:

  • Subjects who are alcoholics or regular drinkers within 6 months prior to screening, that is, consuming more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of spirits with 40% alcohol or 150 mL of wine); or have positive results of alcohol breath tests during the screening period and baseline period; and cannot abstain during the trial;
  • Subjects who smoke more than 5 cigarettes per day or habitually use nicotine-containing products in 3 months prior to screening, and cannot abstain during the trial;
  • Subjects who abuse drugs or have used soft drugs (such as: marijuana) in 3 months prior to screening or hard drugs (e.g.: cocaine, amphetamines, phencyclidine, etc.) within 1 year prior to screening; or have positive results of urine drug abuse tests during the screening period and baseline period;
  • Subjects who habitually drink grapefruit juice or excessive tea, coffee and/or caffeinated beverages and cannot abstain during the trial or have previous withdrawal syndrome;

Other:

  • Subjects who cannot tolerate venipuncture, or have history of fear of needles and hemophobia;
  • Subjects who are engaged in work with long-term exposure to radioactive conditions; or have significant radioactive exposure within 1 year prior to the trial (≥2 chest/abdominal CT, or ≥3 other types of X-ray examinations) or have participated in trials with radiolabeled drugs;
  • Subjects who have had blood loss or donated more than 400 mL of blood within 3 months prior to screening, or received blood transfusion within 1 month;
  • Subjects who have any other factors that are not suitable for participating in this trial in opinion of the investigator.
  • Subjects who have any other factors that are not suitable for participating in this trial in opinion of the investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    [14C]STI-1558

    Drug: [14C]STI-1558

Interventions

  • DrugSTI-1558Studies of STI-1558STI-1558 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Fasting oral administration of 600 mg \[ 14C \] STI-1558 ( about 100 μCi ) solution.

06

What researchers measure

Primary outcomes

  1. Distribution Ratio of the Total Radioactivity in Whole Blood and in Plasma.

    To investigate the distribution ratio of the total radioactivity in whole blood and plasma after oral administration of \[14C\]STI-1558 in healthy subjects。

    Time frame: Blood samples collected:Within 1hour before administration of [14C]STI-1558 and 0.25、0.5、1、1.5、2、 3、4、6、8、12、24、48、72、120 、168 hours after administration.

  2. Total Radioactivity in Whole Blood and in Plasma:AUC[0-t].

    To investigate the pharmacokinetic profiles of the total radioactivity in whole blood and plasma after oral administration of \[14C\]STI-1558 in healthy subjects.

    Time frame: Blood samples collected:Within 1hour before administration of [14C]STI-1558 and 0.25、0.5、1、1.5、2、 3、4、6、8、12、24、48、72、120 、168 hours after administration.

  3. Total Radioactivity in Whole Blood and in Plasma:Cmax .

    To investigate the pharmacokinetic profiles of the total radioactivity in whole blood and plasma after oral administration of \[14C\]STI-1558 in healthy subjects。

    Time frame: Blood samples collected:Within 1hour before administration of [14C]STI-1558 and 0.25、0.5、1、1.5、2、 3、4、6、8、12、24、48、72、120 、168 hours after administration.

  4. Total Radioactivity in Whole Blood and in Plasma:AUC[0-inf].

    To investigate the pharmacokinetic profiles of the total radioactivity in whole blood and plasma after oral administration of \[14C\]STI-1558 in healthy subjects。

    Time frame: Blood samples collected:Within 1hour before administration of [14C]STI-1558 and 0.25、0.5、1、1.5、2、 3、4、6、8、12、24、48、72、120 、168 hours after administration

  5. Total Radioactivity in Whole Blood and in Plasma:Tmax.

    To investigate the pharmacokinetic profiles of the total radioactivity in whole blood and plasma after oral administration of \[14C\]STI-1558 in healthy subjects。

    Time frame: Blood samples collected:Within 1hour before administration of [14C]STI-1558 and 0.25、0.5、1、1.5、2、 3、4、6、8、12、24、48、72、120 、168 hours after administration.

  6. Total Radioactivity in Whole Blood and in Plasma:t1/2.

    To investigate the pharmacokinetic profiles of the total radioactivity in whole blood and plasma after oral administration of \[14C\]STI-1558 in healthy subjects。

    Time frame: Blood samples collected:Within 1hour before administration of [14C]STI-1558 and 0.25、0.5、1、1.5、2、 3、4、6、8、12、24、48、72、120 、168 hours after administration.

  7. Total Radioactivity in the Excreta(Urine).

    To perform the quantitative analysis of the total radioactivity in urine, and obtain the recovery of radioactivity and the main excretion pathways in humans after oral administration of \[14C\]STI-1558 in healthy subjects.

    Time frame: Urine samples collected:-24~0 hours before administration of [14C]STI-1558 and 0~8,8~24,24~48,48~72,72~96,96~120,120~144,144~168,168~192,192~216,216~240,240~264,264~288,288~312, 312~336 hours after administration.

  8. Total Radioactivity in the Excreta(Faeces).

    To perform the quantitative analysis of the total radioactivity in faeces, and obtain the recovery of radioactivity and the main excretion pathways in humans after oral administration of \[14C\]STI-1558 in healthy subjects.

    Time frame: Faeces samples collected:-48~0 hours before administration of [14C]STI-1558 and 0~24,24~48,48~72, 72~96,96~120,120~144,144~168,168~192,192~216, 216~240,240~264,264~288,288~312 ,312~336 hours after administration.

Secondary outcomes

  1. Plasma Concentrations of STI-1558 (active compound AC1115):AUC[0-t].

    To perform the quantitative analysis of plasma concentrations of STI-1558 (active compound AC1115) using validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) to evaluate the plasma pharmacokinetic parameters of STI-1558 (active compound AC1115).

    Time frame: Blood samples collected:Within 1hour before administration of [14C]STI-1558 and 0.25、0.5、1、1.5、2、 3、4、6、8、12、24、48、72、120 、168 hours after administration.

  2. Plasma Concentrations of STI-1558 (active compound AC1115):AUC[0-inf].

    To perform the quantitative analysis of plasma concentrations of STI-1558 (active compound AC1115) using validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) to evaluate the plasma pharmacokinetic parameters of STI-1558 (active compound AC1115).

    Time frame: Blood samples collected:Within 1hour before administration of [14C]STI-1558 and 0.25、0.5、1、1.5、2、 3、4、6、8、12、24、48、72、120 、168 hours after administration.

  3. Plasma Concentrations of STI-1558 (active compound AC1115):Cmax.

    To perform the quantitative analysis of plasma concentrations of STI-1558 (active compound AC1115) using validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) to evaluate the plasma pharmacokinetic parameters of STI-1558 (active compound AC1115).

    Time frame: Blood samples collected:Within 1hour before administration of [14C]STI-1558 and 0.25、0.5、1、1.5、2、 3、4、6、8、12、24、48、72、120 、168 hours after administration.

  4. Plasma Concentrations of STI-1558 (active compound AC1115):Tmax .

    To perform the quantitative analysis of plasma concentrations of STI-1558 (active compound AC1115) using validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) to evaluate the plasma pharmacokinetic parameters of STI-1558 (active compound AC1115).

    Time frame: Blood samples collected:Within 1hour before administration of [14C]STI-1558 and 0.25、0.5、1、1.5、2、 3、4、6、8、12、24、48、72、120 、168 hours after administration.

  5. Plasma Concentrations of STI-1558 (active compound AC1115):t1/2 .

    To perform the quantitative analysis of plasma concentrations of STI-1558 (active compound AC1115) using validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) to evaluate the plasma pharmacokinetic parameters of STI-1558 (active compound AC1115).

    Time frame: TBlood samples collected:Within 1hour before administration of [14C]STI-1558 and 0.25、0.5、1、1.5、2、 3、4、6、8、12、24、48、72、120 、168 hours after administration.

  6. Plasma Concentrations of metabolite M10:AUC[0-t].

    To perform the quantitative analysis of plasma concentrations of metabolite M10 using validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) to evaluate the plasma pharmacokinetic parameters of metabolite M10.

    Time frame: Blood samples collected:Within 1hour before administration of [14C]STI-1558 and 0.25、0.5、1、1.5、2、 3、4、6、8、12、24、48、72、120 、168 hours after administration.

  7. Plasma Concentrations of metabolite M10:AUC[0-inf].

    To perform the quantitative analysis of plasma concentrations of metabolite M10 using validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) to evaluate the plasma pharmacokinetic parameters of metabolite M10.

    Time frame: Blood samples collected:Within 1hour before administration of [14C]STI-1558 and 0.25、0.5、1、1.5、2、 3、4、6、8、12、24、48、72、120 、168 hours after administration.

  8. Plasma Concentrations of metabolite M10:Cmax.

    To perform the quantitative analysis of plasma concentrations of metabolite M10 using validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) to evaluate the plasma pharmacokinetic parameters of metabolite M10.

    Time frame: Blood samples collected:Within 1hour before administration of [14C]STI-1558 and 0.25、0.5、1、1.5、2、 3、4、6、8、12、24、48、72、120 、168 hours after administration.

  9. Plasma Concentrations ofmetabolite M10:Tmax .

    To perform the quantitative analysis of plasma concentrations of metabolite M10 using validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) to evaluate the plasma pharmacokinetic parameters of metabolite M10.

    Time frame: Blood samples collected:Within 1hour before administration of [14C]STI-1558 and 0.25、0.5、1、1.5、2、 3、4、6、8、12、24、48、72、120 、168 hours after administration.

  10. Plasma Concentrations of metabolite M10:t1/2.

    To perform the quantitative analysis of plasma concentrations of metabolite M10 using validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) to evaluate the plasma pharmacokinetic parameters of metabolite M10.

    Time frame: Blood samples collected:Within 1hour before administration of [14C]STI-1558 and 0.25、0.5、1、1.5、2、 3、4、6、8、12、24、48、72、120 、168 hours after administration.

  11. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.

    To observe the safety of subjects after a single dose of \[14C\]STI-1558 until sample collection is complete.

    Time frame: From administration of [14C]STI-1558 to Day14.

07

Study locations

1 site
  • Beijing Gaobo Boren Hospital
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Jun 2023, 1 month.

Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's 1 month is below that.

Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2023
First posted
Mar 3, 2023
StartActual
May 15, 2023
Primary completionActual
Jun 22, 2023
CompletionActual
Nov 9, 2023
Last update
Dec 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05754411
Lead sponsor
Zhejiang ACEA Pharmaceutical Co. Ltd.
Responsible party
Sponsor
First posted
Mar 3, 2023
Start date
May 15, 2023
Primary completion
Jun 22, 2023
Completion
Nov 9, 2023
Last update
Dec 7, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: STI-1558

Start the discussion